

Drug Shortages:

America's Physician Groups
Deep Dive Webinar Series

Michael Ganio, PharmD, MS, FASHP Senior Director, Pharmacy Practice and Quality American Society of Health-System Pharmacists



Agenda

- Brief history and current state of drug shortages
- Managing drug shortages
- Root causes and possible solutions




Drug Shortages: Brief history and current state



Drug Shortages


New Shortages by Year January 2001 to March 31, 2023, % Injectable





Drug Shortages

Active Shortages by Quarter: 5-Year Trend





Drug Shortages


Active Shortages: Top-Five Drug Classes March 31, 2023





Drug shortages


Active Shortages: Common Drug Classes in Short Supply 5-Year Trend





Drug shortages

Reasons for Shortages as Reported by Manufacturers: 2022





Drug Shortages: Managing drug shortages



Clinical Strategies

- Therapeutic alternatives
- Different routes of administration
- Rationing criteria
- Delay or cancel treatment
- Altering order sets or protocols



Operational Strategies

- Consolidate / centralize inventory
- Use non-formulary sizes or concentrations
- "Insource" internal compounding
- Repackaging
- 503B outsourcing facilities
- Secondary wholesaler



ASHP Guidelines

ASHP Guidelines on Managing Drug Product Shortages

Purpose

Drug product shortages can adversely affect drug therapy, compromise or delay medical procedures, result in medication errors, and cause patient harm. In addition to these potential problems, healthcare professionals are also increasingly concerned about the tremendous resources required to address shortages, estimated at \$209 million in 2013 for the purchase of more-expensive substitutes alone, which excludes other significant costs (e.g., drugs purchased "off contract" therapeutic alternatives added labor) 39,40

efficacious, have a worse adverse-effect profile, or require an unusual or difficult dosing regimen. Best practices for managing drug shortages must first consider the potential impact on patient safety. Data documenting patient harm due to drug shortages are limited to case reports and survey data. The Institute for Safe Medication Practices (ISMP) is the leading source of aggregate data. ^{13,15,16} A medication-error reporting and review system is an essential component of a medication safety system. Errors and near misses should be reported internally and externally, and analyzed. ^{48,49}

https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.ashx



Drug Shortages: Root causes and possible solutions


























Root causes

Drug Shortages:

Root Causes and Potential Solutions

2019









https://www.fda.gov/media/132058/download

- Root Cause 1: Lack of Incentives to Produce Less Profitable Drugs. When market conditions
 limit manufacturers' profitability, they reduce a firm's motivation to maintain a presence in, or enter
 the market for older prescription drugs, and to invest in manufacturing quality and redundant capacity.
 Manufacturers of older generic drugs, in particular, face intense price competition, uncertain revenue
 streams, and high investment requirements, all of which limit potential returns. Current contracting
 practices contribute to a "race to the bottom" in pricing.
- Root Cause 2: Market Does Not Recognize and Reward Manufacturers for Mature Quality Management Systems. All manufacturers must meet regulatory requirements for adherence to Current Good Manufacturing Practices (CGMPs), which set a minimum threshold that companies must achieve in order to be allowed to supply the U.S. marketplace. Mature quality management, however, starts with a foundational quality management system that conforms to CGMPs and builds in a performance and patient focus that utilizes technology, statistical process control, and planning activities to ensure a reliable supply of the drugs manufactured at the facility.


Currently, purchasers have only limited information that can be used to assess the state of quality management of any specific facility and have little information linking the drug products they buy with the facilities where they were manufactured. The lack of information does not enable the market to reward drug manufacturers with price premiums for mature quality management, back-up manufacturing capabilities, or risk-management plans, nor does it penalize manufacturers that fail to invest in modernization of manufacturing equipment and facilities to ensure a reliable supply. Thus, manufacturers are more likely to keep costs down by minimizing investments in manufacturing quality, which eventually leads to quality problems, triggering supply disruptions and shortages.





https://www.fiercepharma.com/manufacturing/akorn-pharma-bankrupt-calls-it-quits-closes-all-us-sites-and-cuts-entire-workforce






https://www.reuters.com/markets/deals/drugmaker-athenex-voluntarily-files-us-chapter-11-

proceedings-2023-05-14/



all-us-sites-and-cuts-entire-workforce





FIERCE
Pharma

Manufacturing Marketing Pharma Vaccines Special Reports Trending Podcasts

MANUFACTURING
Bankrupt Akorn Pharma calls it
f quits and closes all US sites, laying
off entire workforce
By Zoey Becker • Feb 23, 2023 10:12am

https://www.fiercepharma.com/manufacturing/akorn-pharma-bankrupt-calls-it-guits-closes-

all-us-sites-and-cuts-entire-workforce

https://www.reuters.com/markets/deals/drugmaker-athenex-voluntarily-files-us-chapter-11-

proceedings-2023-05-14/

Bloomberg

Markets

Teva Plans to Cut Back Generic Drug Production Even As Shortages Intensify

- Drugmaker will focus on new, branded products to fuel growth
- Manufacturing reductions will not harm market supply: CEO

https://www.bloomberg.com/news/articles/2023-05-18/teva-plans-cuts-to-generic-drug-production-amid-shortages#xj4y7vzkg





https://www.fiercepharma.com/manufacturing/burn-after-reading-fda-blasts-intas-cascade-failures-after-investigators-find-heaps



Solutions

- Address the root causes incentivize investment in quality maturity
- Mitigate the impact reimagine the strategic national stockpile
- Build better systems adopt newer manufacturing technologies
- Improve transparency identify vulnerabilities so they can be addressed



Drug Shortages – Discussion







Drug Shortages:

America's Physician Groups Deep Dive Webinar Series

Michael Ganio, PharmD, MS, FASHP Senior Director, Pharmacy Practice and Quality American Society of Health-System Pharmacists

